Core Points - The COLOR RUN, known as "the happiest 5K on Earth," recently took place in Beijing with nearly 20,000 participants, promoting health awareness and community engagement [1] - The event was organized in collaboration with the Peking University-Stanford Asian Liver Center, aiming to raise public awareness about liver health and combat stigma associated with hepatitis B [1][3] - The event featured interactive activities, including a "Jade Ribbon" wall for participants to leave colorful handprints and learn about hepatitis B through fun quizzes [1] Health Statistics - According to the World Health Organization (WHO), one person dies from hepatitis-related diseases every 30 seconds, with 80% of infected individuals unaware of their condition [2] - In China, approximately 80 million people are carriers of the hepatitis B virus, equating to 1 in every 14 individuals [2] - China accounts for 31.5% of the global hepatitis B patient population, with about 17 million diagnosed individuals needing antiviral treatment, yet only 3 million currently receiving it [2] Community Engagement - The event attracted various influential organizations and student groups, including the Peking University Love Charity Society, to support the cause and challenge hepatitis B discrimination [1][2] - The center's leader emphasized the importance of promoting liver health through enjoyable activities, aiming to bridge the gap caused by stigma surrounding hepatitis B [3]

Core Viewpoint - The event "Together, Towards a Future Without Hepatitis B" highlights the achievements and ongoing challenges in China's hepatitis B prevention and control efforts over the past 30 years, emphasizing the importance of a collaborative approach involving government, multiple sectors, and society as a whole [1][2]. Group 1: Achievements in Hepatitis B Prevention - China's comprehensive prevention and control work for hepatitis B has shown significant results, with a focus on policy guidance, funding, team building, scientific research, and social security [1]. - The country is at a critical historical juncture in the global goal to eliminate viral hepatitis, with the "Chinese experience" expected to contribute significantly to global health [1]. Group 2: Challenges and Future Goals - Despite progress, challenges remain in achieving the goal of eliminating viral hepatitis by 2030, necessitating a collective effort to address these issues [1]. - There is a need for public health measures to improve the diagnosis and treatment rates of hepatitis B to effectively reduce the incidence of related liver cirrhosis and liver cancer [2]. Group 3: Advances in Treatment - Over the past 30 years, advancements in hepatitis B treatment have led to improved drug efficacy and safety, alongside reduced costs [2]. - The development of new therapies aimed at achieving "functional cure" for hepatitis B is crucial to overcoming the current limitation of long-term treatment for most patients [2].

Core Viewpoint - The article emphasizes the importance of early screening and treatment for chronic hepatitis B virus (HBV) infection to reduce the incidence of liver cirrhosis and liver cancer in China, highlighting the need for public awareness and family involvement in prevention efforts [1][2][3]. Summary by Sections Achievements in Hepatitis B Control - Over the past 30 years, China has made significant progress in controlling viral hepatitis, particularly chronic HBV infection, with the hepatitis B surface antigen positivity rate decreasing from 9.72% in 1992 to 5.86% in 2020, a reduction of over 39% [2]. Risks of Untreated Chronic HBV - Chronic HBV infection is a major cause of liver cirrhosis and liver cancer, with annual incidence rates of 2%-10% for cirrhosis and 3%-6% for liver cancer among untreated patients [2]. - The primary age group affected by chronic HBV infection is between 35 and 55 years, which is critical for family and societal support [2]. Misconceptions About Treatment - There are common misconceptions among the public regarding the necessity of treatment for asymptomatic patients, with a strong emphasis on the need for early antiviral therapy to suppress HBV replication and prevent disease progression [2][3]. - Psychological burdens and stigma associated with HBV infection hinder patients from seeking treatment, with 74% of infected individuals fearing transmission to family members [2]. Recommendations for Prevention and Treatment - It is recommended that adults undergo at least one HBV screening in their lifetime, and those over 30 or with a family history of liver disease should receive antiviral treatment as needed [3][4]. - Family involvement in HBV screening and treatment is crucial for early detection and support, which can help prevent disease progression and improve quality of life [3]. Treatment Accessibility and Innovations - Approximately 95% of chronic HBV infected individuals should be receiving treatment according to current antiviral guidelines, with many effective and safe medications now included in health insurance plans, improving accessibility and affordability [4].